Your CFH/ARMS2 AMD Risk Result, Explained: What Research Really Says About Going Blind

Your CFH/ARMS2 AMD Risk Result, Explained: What Research Really Says About Going Blind

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A 23andMe “higher likelihood” tied to CFH (Y402H) and ARMS2 (A69S) reflects two of the strongest common risk variants for age-related macular degeneration (AMD) found in genome-wide studies. But research shows these are susceptibility variants, not destiny. They raise your odds along a spectrum; they do not guarantee vision loss. AMD is diagnosed by an eye exam, never by a DNA test. The best-supported actions today are quitting smoking, scheduled eye exams, and discussing AREDS2-type supplements with your doctor if you already have intermediate AMD.

What you’ll learn:

• What CFH and ARMS2 variants really mean, and why AMD is not a single-gene disease.
• How to turn scary “odds ratios” into an honest, absolute risk you can understand.
• How AMD is actually diagnosed, and what a DTC report can and cannot tell you.
• What you can start doing now, plus how genetic-privacy laws in the US and Canada protect you.

AMD risk is inherited as susceptibility, not as a single “disease gene”

Age-related macular degeneration damages the macula, the small central part of the retina that handles sharp, straight-ahead vision. It is a leading cause of vision loss in older adults. Many readers picture a “genetic disease” as one broken gene passed down in a clear pattern. AMD does not work that way. Research confirms it is polygenic, meaning many genes and lifestyle factors combine to shape risk.

Think of it like a dimmer switch, not a light switch. A single-gene (Mendelian) condition flips the light on or off. AMD variants only nudge the dimmer up or down. This is very different from the autosomal-dominant conditions many people have heard about, where one copy of a variant reliably causes disease. AMD is a matter of stacked odds, not a single switch.

The largest genome-wide study of AMD analyzed more than 16,000 patients and nearly 18,000 controls. It found 52 independent variants across 34 genomic regions. Out of all of them, CFH and ARMS2/HTRA1 remain among the strongest common risk regions. Here is how the two headline variants compare:

Gene	Variant (rs ID)	What it is	Role in AMD
CFH	Y402H (rs1061170)	Common polymorphism (ordinary DNA spelling difference)	Weakens complement “brake”; among strongest common risk regions
ARMS2	A69S (rs10490924)	Common polymorphism	Second best-studied major AMD gene

There are two forms of AMD. Most people have dry AMD, a slow thinning of the macula with drusen deposits under the retina. Wet (neovascular) AMD is less common but causes faster vision loss through abnormal, leaky blood vessels. Notably, research shows the two forms share most of the same genetics, so the same CFH and ARMS2 variants relate to both.

Inheriting one or two copies shifts your probability higher, but it does not lock in disease. Age, smoking, and diet interact with these variants. Established risk factors include increasing age, family history, and smoking, so genetics is only one leg of a three-legged stool. The story began in 2005, when a genome-wide screen first linked the complement factor H pathway to AMD. If your result worries you, a board-certified genetic counselor can explain what it means for you; the NSGC directory lists over 3,300 counselors across the US and Canada.

Section recap: AMD is a multifactorial condition, not a single-gene one. CFH and ARMS2 variants raise your risk along a spectrum rather than guaranteeing disease.

The complement pathway: why CFH matters biologically

Your body has an immune “cleanup crew” called the complement system. It tags debris and threats for removal. Complement factor H (CFH) acts as the brake that keeps this crew from over-reacting in delicate tissue like the retina. The Y402H change sits in a region of CFH that binds heparin and C-reactive protein, and it weakens that braking control.

Picture a smoke detector with a stuck-on sensor. It keeps sounding even when there is little smoke. When CFH regulation weakens, chronic low-grade inflammation builds under the macula. That inflammation helps form drusen, the fatty deposits linked to AMD. Research ties this complement dysregulation directly to AMD susceptibility, which is why the pathway is such a central character in this story.

The genetic map backs this up. An early large study identified four key chromosomal regions tied to AMD, and all four connect to the complement pathway:

• CFH on chromosome 1q32 — the complement “brake” gene.
• ARMS2/HTRA1 on chromosome 10q26 — the second major risk region.
• C2/CFB on chromosome 6p21 — complement-cascade genes.
• C3 on chromosome 19p13 — a core complement protein and a modern drug target.

When several independent risk genes all point at one biological system, scientists gain confidence that the system is causal, not coincidental. The 2016 consortium study strengthened that case by finding rare coding variants in CFH, CFI, and TIMP3 that point to causal roles.

There is one more clue worth knowing. That same consortium study found the first wet-specific genetic signal near a gene called MMP9. Otherwise, wet and dry AMD share most of their genetics. This tells us the complement story is not the whole picture, but it is the central, most actionable thread so far. It is the thread that led scientists from a 2005 discovery to two approved drugs in 2023.

This biology explains today’s newest drugs, which target complement proteins C3 and C5 directly. The thread runs cleanly from a DNA variant to a treatable disease mechanism. That is unusual and genuinely hopeful. Still, carrying the variant does not mean the cascade is currently harming your retina. A gene sets a tendency; it does not report today’s weather inside your eye. Only an eye exam can show what is happening now. Bring your family history and any direct-to-consumer result to an ophthalmologist or optometrist, and consider a genetic counselor for context.

Section recap: CFH normally restrains complement inflammation in the retina. The Y402H variant loosens that control, which is why the newest drugs target the complement pathway.

From odds ratios to absolute risk: how much does the variant really raise it?

Numbers like “6-fold higher odds” sound terrifying, so it helps to translate them honestly. A meta-analysis of the CFH Y402H variant compared each genotype against the low-risk baseline. Here is what the reported odds ratios look like side by side:

Genotype	Risk copies	Reported odds of AMD vs. baseline
TT (CFH)	0	Baseline (reference)
TC (CFH)	1	~2.5-fold higher
CC (CFH)	2	~6-fold higher
ARMS2 A69S risk allele	—	OR around 3.09
Homozygous CFH (2005 study)	2	7.4-fold higher likelihood

The effect is roughly multiplicative, about 2.5-fold per C allele.

Now for the honest translation. An “odds ratio” compares two groups; it is not your personal chance of disease. Baseline matters. Late AMD is uncommon before age 75 and rises sharply only afterward. So imagine a low starting risk. Even a several-fold increase on a small baseline still leaves most carriers without advanced disease. “Elevated” is not “inevitable.”

Here is the key: relative odds are population statistics, not a personal prediction. Think of a weather forecast. A higher chance of rain is not a guarantee you will get soaked today. Two people can hear the same forecast and have very different afternoons, depending on where they walk and whether they carry an umbrella. Your umbrella here includes not smoking and keeping eye appointments.

Even so, the CFH polymorphism is involved in over half of AMD cases at the population level, with a population attributable risk of about 58.9%. That figure reflects how common and influential the variant is across a whole population, not a personal certainty for you. Age and smoking often matter as much as genotype. It is also worth knowing that polygenic risk scores, which combine many variants into one number, are not yet standard clinical tools for AMD. A genetic counselor can help you weigh your personal picture rather than a headline number.

Section recap: A “higher likelihood” is a population statistic. Elevated odds still leave most carriers free of advanced AMD, and late AMD rises mainly after age 75.

Testing options in the US and Canada: DTC reports vs. a clinical eye exam

A direct-to-consumer (DTC) report like 23andMe Health Predisposition checks a few common variants, such as CFH Y402H and ARMS2 A69S. Third-party services sometimes reinterpret raw AncestryDNA data in a similar way. These reports are authorized as risk information only; they do not diagnose disease. Clinical-grade labs like Invitae and Color test genes far more thoroughly. But for AMD, even a complete genetic panel is not the diagnostic tool. The two approaches answer very different questions:

	DTC report (23andMe, AncestryDNA-derived)	Clinical eye evaluation
What it checks	A few common variants (CFH Y402H, ARMS2 A69S)	The retina itself via dilated exam and OCT imaging
What it tells you	Risk information only; does not diagnose	Diagnoses and stages early/intermediate/advanced AMD
Can it see drusen or leaking vessels?	No — it reads DNA, not your eye	Yes — imaging shows physical findings
Typical cost	Usually paid out-of-pocket	Usually billable to insurance or provincial health plans

Here is the crucial point: AMD is diagnosed by imaging the retina, not by DNA. An eye doctor performs a dilated fundus exam, using drops to widen the pupil and look at the back of the eye. They also use optical coherence tomography (OCT), a scan that photographs the retinal layers in cross-section. That imaging is how early, intermediate, and advanced stages are identified and staged. A DNA report is a weather forecast; the eye exam is looking out the window right now.

Why does the distinction matter so much? Because a DTC panel checks only a handful of common variants. It cannot see your drusen, your macular thinning, or any leaking vessels. Those are physical findings that only imaging reveals. In fact, professional guidance holds that routine genotyping is not recommended to guide standard AMD management or supplement decisions. Your genotype is background context, not a management plan.

Coverage differs too, which matters for real budgets. Dilated eye exams and OCT are typically billable to health insurance or provincial health plans in Canada. DTC kits, by contrast, are usually paid out-of-pocket. NSGC also advises verifying insurance coverage of any genetic counseling or testing before proceeding. Take your DTC result to an ophthalmologist or optometrist, and to an NSGC-certified genetic counselor if you want help interpreting it.

Section recap: DTC reports give risk information only; AMD is diagnosed by a dilated exam and OCT imaging. Eye exams are usually covered, while DTC kits are not.

Interpreting your result: risk information vs. diagnosis vs. uncertainty

It helps to separate three very different things. A susceptibility result means raised probability. A diagnosis means an eye specialist confirmed disease through imaging. And “uncertain” or non-actionable findings mean the test cannot tell you much either way. Mixing these three up causes needless panic or false comfort.

Start with the false-comfort trap. A reassuring DTC result does not rule out AMD. These panels test only a few common variants. They ignore the full polygenic and environmental picture, including your age and smoking history. So a “typical likelihood” screen cannot promise you will stay healthy. Think of a home pregnancy test versus an ultrasound: a screen and a clinical confirmation are not the same tool.

Now the false-panic trap. An alarming result does not confirm current disease; it only estimates probability. Remember that even the highest-odds genotype is not deterministic for any individual. A “higher likelihood” is a reason to get a baseline eye exam, not a reason to assume you are losing your sight. Many carriers reach old age with healthy maculas.

Professional guidance reinforces this. Routine genotyping is not used to steer standard AMD care, which underscores that your DNA result is context, not a verdict. To turn a number into a plan, see two people. First, an NSGC-certified genetic counselor to contextualize the result and discuss family testing. Second, an eye specialist for the actual clinical answer through a dilated exam and imaging.

Section recap: A susceptibility result is not a diagnosis, and a reassuring DTC report does not rule out AMD. Only retinal imaging gives the clinical answer.

Prevention and early detection: AREDS2, quitting smoking, and monitoring

The strongest research-backed action is quitting smoking. The CDC identifies smoking as a leading modifiable AMD risk factor and highlights smoking cessation as the best-supported lifestyle step to reduce AMD risk. If you are a smoker trying to quit, that single change likely does more for your eyes than any supplement. In short, the practical levers you control are:

• Quit smoking — the leading modifiable risk factor and the best-supported lifestyle step.
• Manage cholesterol and blood pressure — both are associated risk factors.
• Discuss AREDS2 supplements with your doctor — but only if you already have intermediate AMD.
• Use an Amsler grid at home — a simple square with a center dot that flags new central-vision distortion.
• Keep scheduled dilated eye exams — imaging catches changes you cannot feel.

On supplements, the evidence is specific and often misunderstood. The National Eye Institute’s AREDS2 trial was a multicenter, randomized, double-masked, placebo-controlled phase 3 study run from 2006 to 2012. It enrolled 4,203 people at high risk of progression to advanced AMD. Adding lutein, zeaxanthin, and omega-3 fatty acids to the original formula produced no additional overall statistically significant reduction in progression. The trial’s value was refining the formula rather than boosting it further.

The refinement mattered for safety. AREDS2 replaced beta-carotene, which had raised lung-cancer risk in smokers, with lutein and zeaxanthin. That makes the modern formula safer for former or current smokers. And in participants with the lowest dietary lutein and zeaxanthin intake, supplementation was linked to roughly 25% lower risk of progression to advanced AMD. So the benefit is real but targeted.

Read the label carefully, though. AREDS2 supplements slow progression in people who already have intermediate AMD; they are not proven to prevent AMD in people who do not have it. So do not start them off a DNA result alone. Discuss them with your doctor after an eye exam has staged your retinas.

There is also a scale reason to take prevention seriously. In the US, AMD already affects more than 9 million people, and that number is projected to rise toward roughly 17.8 million by 2050 as the population ages. You are not alone in this, and the modifiable levers are the same ones that help millions of others. That reframes a scary DNA result as a prompt to act, not a sentence.

For early detection, use an Amsler grid to spot new central-vision distortion at home. If straight lines suddenly look wavy, that is a prompt to call your eye doctor. Pair home monitoring with scheduled dilated exams, since imaging catches changes you cannot feel. Knowing you carry elevated risk mainly earns you one thing. It gives you a concrete reason to keep those appointments and to ask your eye doctor how often to return.

Section recap: Quitting smoking is the best-supported action. AREDS2 supplements slow progression only in people who already have intermediate AMD and should be discussed with a doctor.

The latest treatment landscape and its regulatory status

Standard care for wet (neovascular) AMD is anti-VEGF injections, which block the signal that grows leaky blood vessels. FDA-approved anti-VEGF agents include aflibercept, ranibizumab, and faricimab; Health Canada indications should be verified separately. For late dry AMD, it is important to be honest that there is no cure, only ways to manage and slow the disease. All of these treat diagnosed AMD, not a genetic result.

For geographic atrophy (GA), the advanced form of dry AMD, two complement-targeted drugs arrived in 2023. Both grew directly out of the complement biology described earlier in this article. Here is how the newest GA drugs compare:

Drug (brand)	Target	FDA approval date	Reported effect
Pegcetacoplan (Syfovre)	Complement C3 inhibitor	2023-02-17 (first-ever GA treatment)	Reduced GA lesion-area growth ~22% (OAKS) and ~12% (DERBY) over 12 months
Avacincaptad pegol (Izervay)	Complement C5 inhibitor	2023-08-04	Significant reduction in GA progression rate at 12 months (GATHER1 n=286, GATHER2 n=448)

Geographic atrophy deserves a plain definition. It is a form of advanced dry AMD where patches of the light-sensing retina waste away, creating blind spots that slowly enlarge. That is what these two drugs aim to slow.

The trial numbers set realistic expectations. In the phase 3 OAKS and DERBY trials, monthly pegcetacoplan reduced GA lesion-area growth by about 22% in OAKS and 12% in DERBY over 12 months. Avacincaptad pegol won approval on two phase 3 sham-controlled trials, GATHER1 and GATHER2, which enrolled 286 and 448 participants and both showed a significant reduction in the rate of GA progression at 12 months. These are meaningful slowdowns, not reversals.

Read the fine print carefully. As of this article’s date, neither GA drug carries a Health Canada approval for that indication, so Canadian readers should verify current status rather than assume access. Both drugs slow lesion growth but do not restore lost vision. And neither is prescribed based on a genetic result; they treat diagnosed advanced disease. Think of them as brakes that slow the car, not a reverse gear. Ask a retina specialist whether any therapy applies to your actual exam findings.

Section recap: Anti-VEGF treats wet AMD; the 2023 FDA-approved drugs Syfovre and Izervay slow geographic atrophy but do not restore vision and are not prescribed off a DNA test.

Family, GINA, Canada’s law, and the psychosocial reality of a risk result

Should your adult daughter or your siblings test? Because AMD has late onset and strong modifiable factors, this is best treated as a shared-risk conversation, not an automatic reason for everyone to buy DTC kits. A younger relative may gain more from knowing the lifestyle levers, especially not smoking, than from a susceptibility number they cannot act on yet. A genetic counselor can help a family decide who benefits from testing and who does not.

On insurance, the protections are real but incomplete. Here is what the US Genetic Information Nondiscrimination Act (GINA), passed in 2008, does and does not cover:

• Covered — health insurance: GINA (Title I) and the Affordable Care Act bar health insurers from using genetic information or pre-existing conditions to deny coverage.
• Covered — employment: GINA (Title II) bars employers from using genetic information in employment decisions.
• NOT covered — life insurance.
• NOT covered — disability insurance.
• NOT covered — long-term-care insurance.
• Varies by state: some US states add protections in these lines beyond GINA.

That gap in life, disability, and long-term-care coverage is a genuine blind spot for consumers with a risk result. This is exactly the kind of nuance a genetic counselor can help you navigate before you apply for such policies.

Canadian readers have their own shield. The federal Genetic Non-Discrimination Act received Royal Assent on 2017-05-04. It prohibits requiring an individual to take a genetic test or to disclose results as a condition of a contract or service, including insurance. There are exceptions for health practitioners and researchers. The Supreme Court of Canada upheld its constitutionality in a 2020 decision under Parliament’s criminal-law power. In some respects this is broader than the US GINA because it covers goods, services, and contracts.

Finally, it is normal for a “higher likelihood” result to cause anxiety, especially with a strong family history. The healthy response is to convert worry into a plan. That plan is simple: book a definitive dilated eye exam, and have a genetic counseling conversation to put the number in context.

Section recap: GINA and Canada’s Genetic Non-Discrimination Act protect against discrimination, but GINA leaves a gap for life and disability insurance. Genetic counseling helps families and eases anxiety.

Frequently asked questions

Will I get the disease if I carry the CFH or ARMS2 variant? Not necessarily. These are susceptibility variants that raise your odds along a spectrum, not a certainty. Even homozygous CFH carriers, who show the highest reported odds, are far from guaranteed to lose vision, and late AMD rises mainly after age 75. Only an eye exam can tell you what is happening now.

Will my children or siblings inherit this risk, and should they test? Common risk variants can be shared in families. But AMD’s late onset and modifiable factors make testing a personal decision best made with guidance. A genetic counselor can help your family decide who benefits from testing versus focusing on prevention.

Will this genetic result affect my health or life insurance? In the US, GINA and the ACA protect your health insurance and employment from genetic discrimination. However, GINA does not cover life, disability, or long-term-care insurance. In Canada, the federal Genetic Non-Discrimination Act offers broader protection across contracts, including insurance.

Can my employer find out my genetic result? Under GINA, US employers cannot use your genetic information to make employment decisions. In Canada, requiring genetic test disclosure as a condition of a contract or service is prohibited. For your situation, confirm details with a genetic counselor or the relevant agency.

Should I get a second opinion before acting on this? Yes, and from the right specialists. See an ophthalmologist or optometrist for the actual diagnosis through a dilated exam and OCT. See an NSGC-certified genetic counselor to interpret the DNA result. A DNA report alone should never drive treatment or supplement decisions. Even the newest drugs are prescribed only for diagnosed advanced disease, never off a genotype.

Summary

A CFH/ARMS2 “higher likelihood” result reflects two of the most replicated common risk variants for AMD, but research is clear that they raise probability rather than seal fate. AMD is polygenic, shaped by age, smoking, and diet as much as genes. It is diagnosed by retinal imaging, not by DNA, so a DTC report is a starting point, not an answer.

The most useful steps are practical. Quit smoking, keep scheduled dilated exams, and monitor with an Amsler grid. Discuss AREDS2 supplements with a doctor only if you already have intermediate AMD. The 2023 complement drugs Syfovre and Izervay slow geographic atrophy but do not restore vision and are never prescribed off a genotype. Legal protections exist in both countries, with a known GINA gap for life and disability coverage. Turn the result into a plan with an eye specialist and a genetic counselor.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. National Eye Institute (NEI), NIH — Age-Related Macular Degeneration. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration
2. Klein RJ, Zeiss C, Chew EY, et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration. Science, 2005. https://pubmed.ncbi.nlm.nih.gov/15761121/
3. Fritsche LG, Igl W, Bailey JNC, et al. (International AMD Genomics Consortium). A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature Genetics, 2016. https://www.nature.com/articles/ng.3448
4. Age-Related Eye Disease Study 2 (AREDS2) Research Group; Chew EY, Clemons TE, et al. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration (AREDS2). JAMA, 2013. https://pubmed.ncbi.nlm.nih.gov/23644932/
5. U.S. Food and Drug Administration / Apellis Pharmaceuticals — FDA Approval of SYFOVRE (pegcetacoplan) for Geographic Atrophy Secondary to AMD, 2023. https://investors.apellis.com/news-releases/news-release-details/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only
6. U.S. Food and Drug Administration / Iveric Bio (Astellas) — FDA Approval of IZERVAY (avacincaptad pegol) for Geographic Atrophy Secondary to AMD, 2023. https://www.ahdbonline.com/web-exclusives/fda-approvals/fda-approved-izervay-for-the-treatment-of-geographic-atrophy-secondary-to-age-related-macular-degeneration
7. Centers for Disease Control and Prevention (CDC) — About Age-Related Macular Degeneration. https://www.cdc.gov/vision-health/about-eye-disorders/age-related-macular-degeneration.html
8. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Human Molecular Genetics, 2006. https://pubmed.ncbi.nlm.nih.gov/16905558/
9. American Academy of Ophthalmology (AAO) — Age-Related Macular Degeneration Preferred Practice Pattern. Ophthalmology, 2019/2024. https://www.aaojournal.org/article/S0161-6420(19)32091-3/fulltext
10. StatPearls, NCBI Bookshelf — Macular Degeneration, 2023. https://www.ncbi.nlm.nih.gov/books/NBK560778/
11. National Society of Genetic Counselors (NSGC) — Find a Genetic Counselor. https://findageneticcounselor.nsgc.org/
12. National Human Genome Research Institute (NHGRI), NIH — Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
13. Government of Canada, Justice Laws Website — Genetic Non-Discrimination Act (S.C. 2017, c. 3). https://laws-lois.justice.gc.ca/eng/annualstatutes/2017_3/page-1.html

---

Last updated: 2026-08-09 Author: genelumen editorial team. This article aggregates 13 sources from peer-reviewed medical literature and public health agencies (tier 1=9 / tier 2=4), including the NIH/National Eye Institute, the CDC, the NHGRI, the FDA, the American Academy of Ophthalmology, the Government of Canada (Justice Laws), and PubMed-indexed publications. This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan). Related: Genetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-genetic-diseases/amd-cfh-arms2-genetic-risk